Undaunted Bio
Seed-stage company developing repurposed small-molecule therapies for neuropathic pain using a clinically informed, AI-driven, network-medicine approach. Current development focuses on reformulating an existing, previously marketed drug into an oral thin film for treatment of trigeminal neuralgia, with pre-IND status and plans to commence human trials in early 2026 using the FDA 505(b)(2) pathway.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Repurposed drug candidate reformulated as oral thin film (pre-IND)
Development of a reformulated version of an existing drug into an oral thin film dosage form intended to treat trigeminal neuralgia, with plans to broaden indications to other neuropathic pain conditions.
Relationship with You+Others
A combined membership option covering both self-relationship and interpersonal relationships.
Repurposed drug candidate reformulated as oral thin film (pre-IND)
Development of a reformulated version of an existing drug into an oral thin film dosage form intended to treat trigeminal neuralgia, with plans to broaden indications to other neuropathic pain conditions.
Relationship with You+Others
A combined membership option covering both self-relationship and interpersonal relationships.
Expertise Areas
- Drug repurposing
- AI-driven drug discovery
- Neuropathic pain therapeutics development
- Oral thin film formulation development
Key Technologies
- Large language models (LLMs)
- Knowledge graphs
- Machine learning / AI for drug discovery
- Generative chemistry
News & Updates
Company states it is on track to commence human trials in early 2026 with an approval targeting timeline.
Lead repurposed drug candidate for trigeminal neuralgia is described as being at pre-IND clinical stage.
Investor pitch deck and one-page investor summary are available for download.
Company states it is on track to commence human trials in early 2026 with an approval targeting timeline.
Lead repurposed drug candidate for trigeminal neuralgia is described as being at pre-IND clinical stage.
Investor pitch deck and one-page investor summary are available for download.